Oritavancin for acute bacterial skin and skin structure infections

Analysis of the Phase 3 ESTABLISH Trials of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections

(2014) Andrew F. Shorr et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antistaphylococcal Activity of Oritavancin and Its Synergistic Effect in Combination with Other Antimicrobial Agents

(2014) Gengrong Lin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Incidence and cost of hospitalizations associated with Staphylococcus aureusskin and soft tissue infections in the United States from 2001 through 2009

(2014) Jose A Suaya et al.   BMC INFECTIOUS DISEASES

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

(2014) Martin E Stryjewski et al.   BMC INFECTIOUS DISEASES

Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study

(2014) G. Ralph Corey et al.   CLINICAL INFECTIOUS DISEASES

Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide

(2014) R. E. Mendes et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13)

(2014) R. E. Mendes et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections

(2014) G. Ralph Corey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacology and the Treatment of Complicated Skin and Skin-Structure Infections

(2014) Henry F. Chambers   NEW ENGLAND JOURNAL OF MEDICINE

Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection

(2014) Helen W. Boucher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Methicillin-Resistant Staphylococcus aureus Therapy: Past, Present, and Future

(2013) K. A. Rodvold et al.   CLINICAL INFECTIOUS DISEASES

Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study

(2013) J. Garau et al.   CLINICAL MICROBIOLOGY AND INFECTION

Pharmacodynamics of a Simulated Single 1,200-Milligram Dose of Oritavancin in anIn VitroPharmacokinetic/Pharmacodynamic Model of Methicillin-Resistant Staphylococcus aureus Infection

(2012) Adam Belley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Oritavancin: A New Opportunity for Outpatient Therapy of Serious Infections

(2012) A. Tice   CLINICAL INFECTIOUS DISEASES

Macrophage Killing of Bacterial and Fungal Pathogens Is Not Inhibited by Intense Intracellular Accumulation of the Lipoglycopeptide Antibiotic Oritavancin

(2012) Beverlie Baquir et al.   CLINICAL INFECTIOUS DISEASES

In Vivo Activity of Oritavancin in Animal Infection Models and Rationale for a New Dosing Regimen in Humans

(2012) P. G. Ambrose et al.   CLINICAL INFECTIOUS DISEASES

Summary of Ceftaroline Fosamil Clinical Trial Studies and Clinical Safety

(2012) Thomas M. File et al.   CLINICAL INFECTIOUS DISEASES

Oritavancin: Mechanism of Action

(2012) George G. Zhanel et al.   CLINICAL INFECTIOUS DISEASES

The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)

(2012) B.Y. Lee et al.   CLINICAL MICROBIOLOGY AND INFECTION

Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and  -haemolytic streptococci collected from western European countries in 2011

(2012) I. Morrissey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

PIN22 Economic Burden of Hospitalization With Antibiotic Treatment for Absssi in the United States: An Analysis Ofthe Premier Hospital Database

(2012) K.T. LaPensee et al.   VALUE IN HEALTH

Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: an Analysis of the SIMPLIFI Trial

(2011) Lala M. Dunbar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens

(2010) E. Rubinstein et al.   CLINICAL INFECTIOUS DISEASES

In vitro activity of oritavancin against community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)

(2010) Louis D. Saravolatz et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia

(2009) C. M. Rubino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium

(2009) G. A. McKay et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing

(2008) F. F. Arhin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms

(2008) Martin E. Stryjewski et al.   CLINICAL INFECTIOUS DISEASES

High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia

(2008) M. Sharma et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES